Agilent Technologies and Biotek Instruments announced a new, integrated solution that combines cellular metabolic analysis and imaging technologies.
Santa Clara/USA — The optimized solution integrates the Agilent Seahorse XFe96/XFe24 Analyzers with the Biotek Cytation 1 Cell Imaging Multi-Mode Reader. This solution creates a standardized approach for comparing XF data sets, improving assay workflow, embedding images into Wave software, and applying normalization values to Seahorse XF measurements, the companies announced.
According to Gary Barush, Global Director of Marketing and Sales at Biotek, the new approach created a distinct opportunity for cell biology researchers to fully normalize and analyze samples to answer challenging questions regarding cellular metabolism. David Ferrick, Ph.D., Senior Director of Agilent's Cell Analysis Division, added that customers benefit from an optimized method for verifying assay results, and enabling more meaningful data comparisons provided by the data-rich assays. This integrated solution gave their customers the ability to compare XF data on a well-to-well, plate-to-plate, and experiment-to-experiment basis.
The new solution allows researchers to toggle between XF data, brightfield images, and fluorescence images in a unified software experience. Referencing the images while analyzing XF data provides evidence and guidance on how to limit variability and improve the reproducibility of their XF assays. Applying a cell count based normalization value ultimately makes interpreting Seahorse XF data and finding relationships amongst the data easier.
The partners will jointly market the integrated solution, planned for release in the US and Europe in April 2018, and the rest of the world by June 2018.